Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239092 · ClinicalTrials.gov registry record · Phase 1
9-ING-41 in Pediatric Patients With Refractory Malignancies.
A Phase 1 study, sponsored by Actuate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04239092: Clinical Trial Phase 1 study, sponsored by Actuate Therapeutics.
NCT04239092 is a Phase 1 study that was terminated before completion, run by Actuate Therapeutics. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04239092, a Phase 1 study, was terminated before completion, sponsored by Actuate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
Primary Outcome
The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 5 will be conduced at each protocol-specified timepoint.
Interventions
- DRUG Cyclophosphamide
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG Topotecan
- DRUG 9-ING-41
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-06-05 |
| Est. Completion | 2025-07-07 |
| Phase | Phase 1 |
Why NCT04239092 stopped before completion
NCT04239092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04239092 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04239092 about?
NCT04239092 is a clinical study titled "9-ING-41 in Pediatric Patients With Refractory Malignancies.". 9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
What is the current status of trial NCT04239092?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-06-05. Estimated completion is 2025-07-07.
What interventions are being tested in trial NCT04239092?
The interventions under investigation include: Cyclophosphamide (DRUG), Temozolomide (DRUG), Irinotecan (DRUG), Topotecan (DRUG), 9-ING-41 (DRUG).
Who is sponsoring clinical trial NCT04239092?
This trial is sponsored by Actuate Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04239092's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI